Branded Generics In Emerging Market :Global Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Global Branded Generics In Emerging Market By Disease Indication (Cardiovascular Diseases, Diabetes, Cancer, Neurological Disorders, Gastrointestinal Diseases, Dermatology Diseases, and Others), By Route of Administration (Oral, Parenteral, Topical, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Branded Generics in Emerging Market size was estimated at USD USD 250.7 Bn in 2021, growing at a CAGR of 6.3% during the forecast period 2022-2028. This report gives a comprehensive outlook on branded generics across the emerging countries with special emphasis on key regions such as BRICS, ASEAN, and Latin America regions. This report on branded generics in the emerging markets gives historical, current, and future market sizes (US$ Mn) of disease indications, route of administration, distribution channels, and geographic regions. This report market dynamics in emerging countries elaborately to identify the current trends & drivers, future market opportunities, and possible challenges to the key stakeholders operating in the market. In addition, branded generics in the emerging countries report includes new product introductions, recent drug patent expiration data, regulatory scenario, collaborations & distribution agreements, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the branded generics market in emerging countries to better equip the clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Disease Opportunities). Key stakeholders of the market report include suppliers, manufacturers, marketers, engaged in the manufacturing and supply of pharmaceutical products. The rising demand for affordable and high-quality medicines in emerging countries and local government’s initiative improve healthcare access by means of building healthcare infrastructure and price regulations paving the way for branded generics, which enjoys loyalty from larger stakeholders. Moreover, the mixed demographic profile, rising chronic diseases creating the demand for high-quality branded drugs in emerging countries. However, unique players need to understand the unique challenge of access and affordability in the region to withstand current market competition and to derive a long-term strategy.

Branded Generics In Emerging Market

MARKET SUMMARY
-
6.3% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 6.3%
  • Largest Market– Asia-pacific
  • Fastest Growing Market– Latin America

Branded Generics In Emerging Market

  • The report on global Branded Generics In Emerging Market gives historical, current, and future market sizes (US$ Bn) on the basis of Diseases Indication, Route of Administration, Distribution Channel and region
  • Branded Generics In Emerging Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Abbott Laboratories (U.S.)
  • Apotex Inc. (Canada)
  • AstraZeneca (U.K)
  • GlaxoSmithKline plc (U.K)
  • Mylan N.V. (U.S.)
  • Pfizer Inc. (U.S)
  • Sanofi (France)
Drivers And Restraints

Branded Generics In Emerging Market

Rise in out-of-pocket healthcare expenditure and vast market opportunities expected to drive market revenue growth significantly. The healthcare spending as % of total private healthcare expenditure is high in major countries such as India, China, and Brazil, which is likely to impact market growth positively over the forecast period. For instance in 2014, According to World Bank global health expenditure database, Out-of-pocket health expenditure (% of private expenditure on health) in India and China were 89.2% and 72.3% respectively. Moreover, several countries in emerging markets witnessing growing middle-class and rise in incomes, which is expected to create significant demand for branded generics in the emerging countries. In addition, emerging countries account for more than 50% of branded generics sales across the globe, this helps the multinational and local pharmaceutical companies to capitalize the ever-growing market opportunities in the region.


Asia Pacific got significant share

Branded Generics In Emerging Market

Asia-pacific region leads the branded generics market in emerging market in terms of revenue in 2016 and projected to remain dominant across the forecast period owing to high out-of-pocket healthcare expenditure, rising prevalence of chronic diseases, and growing middle-class population. Latin America presented better growth opportunities for the market players.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market and forecast (2021-2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Segmentation

Branded Generics In Emerging Market


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • Abbott Laboratories (U.S.)
  • Apotex Inc. (Canada)
  • AstraZeneca (U.K)
  • CSPC Pharmaceutical Group Limited. (China)
  • Reddy’s Laboratories Ltd. (India)
  • GlaxoSmithKline plc (U.K)
  • Mylan N.V. (U.S.)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S)
  • Sanofi (France)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Valeant Pharmaceuticals International, Inc. (Canada)
  • Nichi-Iko Pharmaceutical Co., Ltd ( Japan)

Description

Branded Generics in Emerging Market size was estimated at USD USD 250.7 Bn in 2021, growing at a CAGR of 6.3% during the forecast period 2022-2028. This report gives a comprehensive outlook on branded generics across the emerging countries with special emphasis on key regions such as BRICS, ASEAN, and Latin America regions. This report on branded generics in the emerging markets gives historical, current, and future market sizes (US$ Mn) of disease indications, route of administration, distribution channels, and geographic regions. This report market dynamics in emerging countries elaborately to identify the current trends & drivers, future market opportunities, and possible challenges to the key stakeholders operating in the market. In addition, branded generics in the emerging countries report includes new product introductions, recent drug patent expiration data, regulatory scenario, collaborations & distribution agreements, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the branded generics market in emerging countries to better equip the clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Disease Opportunities). Key stakeholders of the market report include suppliers, manufacturers, marketers, engaged in the manufacturing and supply of pharmaceutical products. The rising demand for affordable and high-quality medicines in emerging countries and local government’s initiative improve healthcare access by means of building healthcare infrastructure and price regulations paving the way for branded generics, which enjoys loyalty from larger stakeholders. Moreover, the mixed demographic profile, rising chronic diseases creating the demand for high-quality branded drugs in emerging countries. However, unique players need to understand the unique challenge of access and affordability in the region to withstand current market competition and to derive a long-term strategy.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX